CRISPR Therapeutics $2.4 Billion Cash: Why the Stock Slump Persists
CRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Not all rewards are considered taxable income. Discover what qualifies to keep your finances in check and avoid penalties.
12,857 articlesCRISPR Therapeutics wields a rare card: a cash-rich balance sheet and an approved gene therapy. But the stock refuses...
Markets surge as investors debate mega-valuations tied to founder-led tech giants. This piece breaks down what everyd...
Is 2026 a year for nostalgia in travel? This guide breaks down how nostalgia shapes trips, how to budget for memory-d...
Adobe and Duolingo sit at opposite ends of the tech stock spectrum: one is a cash-generating powerhouse, the other a ...
Europe’s move toward UN-led tax dialogue signals a broader shift in global rules. This article breaks down what that ...
A high-profile wedding, a flash of cameras, and a lesson in personal finance. The moment karlie kloss seen leaving of...
CD rates have paused as investors await the Federal Reserve’s next move. This report explains when to lock in a CD ra...
The auto industry is changing fast, and big, cash-rich automakers may be overlooked. This guide explains why investor...
An anonymous trader using a quiet on-chain footprint has amassed about $7 million in unrealized profits by betting ag...
Aggressive investors chase big upside, and sofi's next breakout: leveraged exposure promises amplified moves. This gu...
A major portfolio pivot is unfolding as 13F data reveals a famous hedge fund manager changing course. Learn why billi...
JPMorgan’s Jamie Dimon reveals a simple, enduring rule that shaped his ascent from a young Harvard MBA assistant to t...